Historical record - last NADAC effective date: 6/15/2016
Product Information
RIBAVIRIN 200 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $1.2755 per EA under NDC 65862029084. Its NADAC has been published 186 times since Nov 28, 2013.
FDA first approved this application on Sep 17, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862029084
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
6/15/2016
Active Ingredients
RIBAVIRINApproval Type
Generic (ANDA)
FDA Application
ANDA079117FDA Approved
9/17/2009
TE Code
AB
On Market Since
9/17/2009
Pharmacological Classes
Price Statistics
The NADAC for RIBAVIRIN 200 MG CAPSULE has been published 186 times since Nov 28, 2013, and over the history we have for it it has risen 73.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2755 per EA |
|---|---|
| All-time high | $2.2763 (Mar 12, 2014) |
| All-time low | $0.4723 (Apr 23, 2014) |
| Median price | $0.8732 |
| Average price | $1.0048 |
| Largest weekly change | +209.4% (Jan 22, 2014) |
| Weeks tracked | 186 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+73.4%
Last surveyed Jun 14, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Ribavirin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ribavirin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nucleoside Analog Antiviral class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIBAVIRIN 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIBAVIRIN 200 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $1.2755 per EA (NDC 65862029084), effective Jun 14, 2017.
How has the price of RIBAVIRIN 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIBAVIRIN 200 MG CAPSULE has risen 73.4%. It has been tracked across 186 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RIBAVIRIN 200 MG CAPSULE?
Since Nov 28, 2013, the NADAC for RIBAVIRIN 200 MG CAPSULE has ranged from a low of $0.4723 (Apr 23, 2014) to a high of $2.2763 (Mar 12, 2014), with a median of $0.8732 per EA.
Are there cheaper alternatives to RIBAVIRIN 200 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of RIBAVIRIN 200 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RIBAVIRIN 200 MG CAPSULE?
RIBAVIRIN 200 MG CAPSULE (NDC 65862029084) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.